About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial
By
Juan Pablo Alderuccio
2 Videos
0 views
July 8, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Recommended
AUTOPLAY
ON
Related
Newest
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
22:09
Scripps Health
New Updates in Frontline DLBCL
Feat.
L. Nastoupil
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
04:04
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
22:11
SOHO Brazil 2024
Has the 1L SoC Truly Changed in Advanced Stage DLBCL?
Feat.
A. Zelenetz
35:24
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
Feat.
G. Nowakowski
08:01
Georg Lenz
Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC
34:36
MyCancerHaven
Frontline DLBCL Treatment Approaches
Feat.
R. Vij,
H. Cherng
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
29:26
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in DLBCL and HL
Feat.
J. Erika Haydu
16:03
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New Algorithm for 2L LBCL
Feat.
J. Westin
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
30:07
Dipenkumar Modi
Current Management of DLBCL From Frontline to Relapsed Disease
33:48
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: B-Cell Lymphoma
Feat.
L. Nastoupil
15:33
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…
Feat.
J. Friedberg
06:09
Insights from 2023 ASH Annual Meeting
CLL/SLL: Outcomes of Pts With Richter's Transformation Without …
Feat.
A. Kittai
28:11
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…
Feat.
M. Rotta
